Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From
Cell surface target
Histologic transformation
NSCLC
Osimertinib
Resistance mechanism
SCLC
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
05
08
2023
revised:
03
12
2023
accepted:
11
12
2023
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
NSCLC transformation to SCLC has been best characterized with In this study, we conducted a single-center retrospective analysis of clinical and genomic characteristics of patients with A total of 34 patients were identified in our study. Median age at initial diagnosis was 58, and median time to SCLC transformation was 24.2 months. 68% were female and 82% were never smokers. 79% of patients were diagnosed as stage IV disease, and over half had brain metastases at baseline. Median overall survival of the entire cohort was 38.3 months from initial diagnoses and 12.4 months from time of SCLC transformation. Most patients harbored SCLC transformation is a potential treatment resistance mechanism in driver-mutant NSCLC. In our cohort of 34
Identifiants
pubmed: 38357092
doi: 10.1016/j.jtocrr.2023.100623
pii: S2666-3643(23)00166-2
pmc: PMC10864847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100623Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243698
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207295
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009666
Pays : United States
Informations de copyright
© 2024 by the International Association for the Study of Lung Cancer.
Références
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
J Clin Oncol. 2019 Feb 1;37(4):278-285
pubmed: 30550363
J Thorac Oncol. 2016 Jun;11(6):e67-72
pubmed: 26751586
J Thorac Oncol. 2018 Oct;13(10):1560-1568
pubmed: 29981927
JCO Precis Oncol. 2022 Dec;6:e2200478
pubmed: 36542817
Cancer Discov. 2023 Jul 7;13(7):1572-1591
pubmed: 37062002
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Clin Oncol. 2017 Sep 10;35(26):3065-3074
pubmed: 28498782
J Clin Oncol. 2022 Feb 20;40(6):611-625
pubmed: 34985916
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
Cancer Cell. 2018 May 14;33(5):801-815
pubmed: 29763622
Br J Cancer. 2019 Oct;121(9):725-737
pubmed: 31564718
Ann Transl Med. 2018 Dec;6(23):464
pubmed: 30603652
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
J Thorac Oncol. 2019 Mar;14(3):e45-e48
pubmed: 30543839